CELC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Celcuity Inc (CELC) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including FDA Priority Review for its NDA, promising clinical trial results expected in Q2, and increased cash reserves. While insider selling and technical indicators are neutral, the overall sentiment and analyst ratings strongly favor a buy decision.
The MACD is below 0 and negatively contracting, indicating a neutral to slightly bearish momentum. RSI is neutral at 61.334, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 117.41), suggesting limited immediate upside but potential for a breakout.
FDA Priority Review for gedatolisib NDA with a goal date of July 17,
Promising Phase 3 clinical trial results expected in Q
Increased cash reserves to $166 million, providing financial stability.
Analysts have raised price targets, with Craig-Hallum setting a target of $141 and Stifel at $125, both maintaining Buy ratings.
Insider selling has increased significantly by 657.10% over the last month.
The company reported a net loss of $51 million for Q4 2025, although this was an improvement YoY.
In Q4 2025, the company reported a net loss of $51 million, an improvement of 39.07% YoY. EPS increased by 14.12% YoY to -0.97. Cash reserves rose to $166 million, providing financial stability despite no revenue growth.
Analysts are bullish on the stock. Craig-Hallum raised the price target to $141, citing pipeline progress and confidence in the NDA filing. Stifel raised the target to $125, reflecting reduced operating expense estimates. Needham also raised the target to $122, maintaining a Buy rating.
